Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$686K Buy
5,341
+550
+11% +$64.4K 0.13% 115
2026
Q1
$576K Buy
4,791
+555
+13% +$64.1K 0.12% 108
2025
Q4
$446K Buy
4,236
+247
+6% +$23.2K 0.09% 131
2025
Q3
$335K Buy
3,989
+6
+0.2% +$494 0.07% 154
2025
Q2
$313K Sell
3,983
-31,083
-89% -$2.47M 0.07% 153
2025
Q1
$3.15M Sell
35,066
-558
-2% -$52.1K 0.82% 33
2024
Q4
$3.54M Sell
35,624
-523
-1% -$53.9K 0.93% 24
2024
Q3
$4.1M Sell
36,147
-1,225
-3% -$146K 1.09% 25
2024
Q2
$4.63M Buy
37,372
+1,106
+3% +$142K 1.33% 23
2024
Q1
$4.79M Buy
36,266
+1,893
+6% +$233K 1.4% 20
2023
Q4
$3.75M Buy
+34,373
New +$3.57M 1.25% 24

Other funds holding MRK

Stonebrook Private's MRK Position: Q2 2026 in Review

Stonebrook Private increased its Merck (MRK) stake by 11% in Q2 2026, buying an estimated $64.4K and bringing the position to 5,341 shares worth $686K. The position accounts for 0.13% of the portfolio, ranked #115.

Stonebrook Private first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.79M in Q1 2024. 3,847 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Stonebrook Private held 5,341 shares of Merck worth $686K as of Q2 2026.
  • Stonebrook Private bought 550 Merck shares in Q2 2026, an estimated $64.4K.
  • Merck made up 0.13% of Stonebrook Private's portfolio in Q2 2026, its #115 holding.
  • Stonebrook Private first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • Stonebrook Private's Merck position peaked at $4.79M in Q1 2024.
  • 3,847 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Stonebrook Private's 13F filing for Q2 2026, filed 14 Aug 2026.